The KEYNOTE-756 trial (NCT03725059) completed accrual and is currently investigating the addition of pembrolizumab to NAT and adjuvant endocrine therapy in high-grade (3/3) ER+ErbB2- breast cancer patients. The gene discussed is BRD2; the disease is breast cancer.